Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education|
|Citation:||American Journal of Pharmaceutical Education, 2010; 74(9):Article 168|
|Publisher:||Amer Assoc Coll Pharmacy|
|David M. Plevin, Helena M. Ward, Michael B. Ward, Michael J Sorich, and Ross A. McKinnon|
|Abstract:||OBJECTIVES: To investigate the pharmacists' role in providing targeted therapies to patients and its implications for pharmacy education. METHODS: Nine pharmacy faculty members, 12 clinical pharmacists, and 4 oncologists from across Australia and New Zealand participated in semistructured interviews, which were analysed using the framework method. RESULTS: Education about targeted therapies was seen as being important, although content about pharmacodiagnostic tests was taught inconsistently among 7 universities. Issues including funding, clinical and diagnostic validity of tests, and time taken for turnaround of tests were perceived as impediments to the acceptance by clinicians of the utility of pharmacodiagnostic tests. CONCLUSIONS: Pharmacists may be the ideal professionals to interpret test results and provide counselling for patients to assist them in compliance with targeted cancer therapies. Pharmacy education in cancer therapies is critical to training pharmacists who can assist patients in the correct use of these therapies.|
|Keywords:||cancer, genomic medicine, monoclonal antibody, pharmacodiagnostics, targeted therapy|
|Rights:||Copyright status unknown|
|Appears in Collections:||Medical Education Unit publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.